SARAH FOX RN, MSN, CNS, CCRC
email: [email protected]
EDUCATION
B.S.N, M.S.N. - Parent/Child Clinical Nurse Specialist Azusa Pacific University, Azusa, California
B.A. (Biology)
State University College at Buffalo, Buffalo, New York A.A. (Nursing)
Trocaire College, Buffalo, New York
Boston University, Boston, Massachusetts (transferred)
PROFESSIONAL EXPERIENCE Azusa Pacific University – 03/2011 to present – AssociateProfessor
Classes taught: Pediatrics, lecture and clinical instructor at CHOC and Rady Children’s Hospital. Assisted with skills lab, SIMS lab. Undergraduate research and on-line research to RN to BSN students. Developed, initiated and lead a 252 hour residency program for Entry level masters students each semester for 20 students. Member of the research committee for SON.
Tibotec Therapeutics 01/2006- 03/2011 Senior Science and Research Liaison, Virology Develop peer-to-peer relationships with thought leaders in practice, academic and research settings, engaging in scientific exchange on research and clinical trends. I provided field based clinical support to thought leaders by responding to unsolicited medical information requests, participating in the identification and facilitation of novel clinical study ideas, and providing educational presentations upon request. I assisted in developing a clinical trials strategy for investigator initiated trials. Additionally, my role assists with site selection and field support of company sponsored trials. I participated in regional symposia, clinical and marketing advisory boards, and other national/regional medical meetings. I attended medical meetings as a full scientific registrant to gather and convey new scientific information useful to thought leaders, to the Company, and to maintaining my professional expertise. I strengthened the bond between Tibotec Therapeutics and the healthcare community by being informative to thought leaders with reliable, objective, medical education, supportive of research endeavors, and receptive to feedback on therapeutic products, clinical trends, and research of interest , through peer-to-peer scientific exchange.
03/2003 – 01/2006 Senior Manager, Clinical Affairs, Chronic Care
Clinical research and educational responsibilities expanded to include Critical Care, Geriatrics, Immunology, Nephrology, and Surgery. Responsible for advanced projects within the team such as
reviewing manuscripts, identifying and developing training programs, and mentoring new managers as well as duties listed below across all of IM/chronic care medicine.
06/2000 – 03/2003 Manager Clinical Affairs, Immunology
Clinical research which includes facilitation of regional involvement in Ortho Biotech immunology clinical research projects; Develop clinical guidelines and pathways with key accounts/thought leaders for appropriate use of Ortho Biotech products; Manage assigned physician IND studies; Work with thought leaders on existing and planned studies or Ortho Biotech Products; Identify potential HIV/HCV thought leaders; Review concept protocols; Help monitor and promote accrual; Answer protocol questions; Participate in conferences and forums; Discussion on off-labelindications. Hire, train, develop and manage clinical associates within Washington, Oregon, California, Arizona, and Nevada. Clinical support to OBI sales force that involves; providing expert clinical consultation, support and education to regional sales force; supporting the development of new markets for Ortho Biotech product in relevant area.
Relationship management and education by participation in regional educational programs of Ortho Biotech products; Presenting lectures to key HIV/HCV customers; Participating in regional symposia and other national/regional cooperative meetings; developing clinical protocol design and management with thought leaders. Provide support to regional strategic planning by partnering with sales districts, Strategic Account Managers and /or assistant medical directors; Participation in regional strategic planning for sale,
marketing, and clinical research; understands regional reimbursement issues; Maintains an up to date knowledge base in HIV and Hepatitis C focusing on areas of opportunities for further research. Azusa Pacific University
09/95 – 06/2000 Associate Professor, Pediatric Clinical Instructor
Childrens Hospital Los Angeles
09/95 –06/2000 Clinical Nurse Specialist/Director of HIV Clinical Research Program
Division of Clinical Immunology – Allergy
Responsible for the Children Hospital Los Angeles (CHLA) AIDS Clinical Trials Program and staff.
Coordinated and facilitated national collaboration of CHLA with ACTG, the National Cancer Institute, UCLA, and pharmaceutical companies. This included writing grant proposals, protocols, informed consents, procurement, development, initiation, and maintenance of new trials. Evaluated patient safety/progress and laboratory results, FDA regulatory requirements and maintains the standards of good clinical practice. Coordinated and educated staffs in the management of patients on study protocols.
Study Coordinator Division of Clinical Immunology-Allergy
in study protocols, which included assessment of clinical and laboratory data. Maintained detailed records using both computer and paper data entry.
CCS Nurse Coordinator Division of Clinical Immunology-Allergy
Responsibilities included working in collaboration with members of the Division of Clinical Immunology in a pediatric ambulatory/inpatient care setting, with a specific focus on the clinical management of patients with immune deficiencies. Organized new systems within the Division to meet the varied needs of the HIV-infected patient. These included chart reviews, team meetings and billing procedures.
09/01/1984- 06/01/2000 Staff Nurse Division of Nephrology
Responsibilities included coordinating the care for the home and hospitalized Pediatric peritoneal dialysis patient. This included physical assessment at monthly clinical and acute visits as indicated, phone
assessment, communicating between different hospital and community services for patient care and follow-up, extensive training of patient and family for home dialysis using a cycler machine and/or manual
technique, in-patient dialysis care and hospital staff teaching. Also conducted home visits to assist families with the transition from hospital care to home care. Trained and competent providing hemodialysis to end stage renal disease patients.
UCLA Medical Center
Clinical Nurse Division of Pediatrics
Charge nurse on the evening shift for the 60-bed floor and 20 bed ICU with direct care and supervision of 10 adolescent patients.
PROFESSIONAL LICENSURE/CERTIFICATION
License: Registered Nurse, California (License # 297052)
License: Certified Clinical Nurse Specialist (License # 390)
Certification: Association of Clinical Research Professionals- exp 10/2016
Certification: Collaborative Institutional Training Initiative (CITI)- Research exp 3-2017)
Certification: BLS (exp 10-2016)
PROFESSIONAL ORGANIZATIONS
Member, Sigma Theta Tau (Honor Society of Nursing) Member, Association of Clinical Research Professionals
AWARDS AND HONORS
2002-2010 Multiple Encore, Standards of Leadership Awards, Ortho Biotech and Tibotec 2001- Horizon Award, Ortho Biotech
1995 - Azusa Pacific Outstanding Graduate Award 1994 - Sigma Theta Tau Research Scholarship 1994 - Kaiser Permanente R.N. Nursing Scholarship
1994 - Azusa Pacific University Excellence in Nursing Award
PUBLICATIONS
Fox, S. Students Biggest Fear When Entering Pediatric Rotations and the Least Addressed. Society of Pediatrics. To be presented April 10-12, 2014. Scottdale, AZ
PRuane, BAlas, RRyan, SFox, APernicario, JWitek, A phase 111b Pilot Study Substituting
Darunavir/ritonavir (DRV/r) and Etravirne (ETR) for Enfuviritide (ENF) and Current PI in a Suppressive Regimen, HIV9, poster #P068, Nov 9-13, 2008, Glasgow, UK.
Church JA, Fox S, Gomperts E. Effects of High-Dose Intravenous Immunoglobulin on Virus Load in HIV-Infected Children. JAIDS Journal of Acquired Immune Deficiency Syndromes. 22(3): 309-311,
November1,1999.
Fox-Wheeler S, Heller LS, Salata CM, Kaufaman F, Loro ML, Gilsanz V, Haight M, Umman GC, Barton N, Church JA. Evaluation of the Effects of Oxandrolone on Malnourished HIV-Positive Pediatric Patients. Pediatrics, 104:6,Dec 1999.
Heller L, Fox-Wheeler S, Hell K, Church JA. Instrument Development to Assess Nutritional Risk Factors for Children with HIV/AIDS. Accepted for publication in the Journal of The American Dietetic Association. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Fox S, et al. A Clinical Trail of Retroviral-Mediated Transfer of an RRE Decoy Gene into CD34+ from the Bone Marrow of HIV-1 Infected Children. Blood, Vol 94,No1 (July 1), 1999: pp368-371.
Wheeler, SF, Heller, LS, Salata,C, Loro ML, Haight M, Kaufmann F, Barton N, Church JA. Evaluation of the Effects of Oxandrolone on Malnourished HIV-Positive Pediatric Patients. 12th World AIDS Conference June
28-July3, 1998, abstr# 12120
Wheeler, SF, Bauer G, Church JA, Transduction of CD34+ Cells From the Bone Marrow of HIV-1 Infected Children: Comparative Marking by an RRE Decoy Gene and a Neutral Gene. The Fifth Conference on Retroviruses and Opportunistic Infections. Feb 2, 1998, abstract #618.
Keller A, Lewis L, Wheeler SF, Lack of Phenotypic Cross- Resistance of 1 Isolates Obtained from HIV-1 Infected Children Receiving Combinations of Lamivudine (3TCÔ), Zidovudine (ZDV) and Didanosine (ddI). The Fifth Conference of Retroviruses and Opportunistic Infections, Feb 3, 1998, abstract # 688.
Mettler ML, Borden K, Wheeler S, Racial and Ethnic Patterns of Disclosure to Children with HIV. Presented at American Psychological Association’s Annual Conference, August 1997.
Mettler ML, Borden K, Wheeler, S, Church JA, Disclosure of HIV Status to School-Age Children with HIV. The Society of Behavioral Medicine Eighteenth Annual Scientific Sessions, April 16, 1997. (abstract) Church JA, Wheeler, S., Gomperts, E. Effects of High-Dose Intravenous Immunoglobulin (IVIG) on Viral Load and T-cell Activation in HIV-Infected Children. The Fourth Conference on Retroviruses and
Opportunistic Infections, January 22, 1997 (abstract 431).
Heller LS, Church JA, Wheeler, S. Nutritional Risk Factors for Children with HIV/AIDS. The Fourth Conference on Retroviruses and Opportunistic Infections, January 22, 1997 (abstract 694).
Kearns, K. Bahner, F, Wheeler, S., Miller, B, Kohn, D. Church, C, Suitability of Bone Marrow from HIV-1-Infected donors for Retroviral-Mediated Gene Transfer. In press, August 1996.
Lewis L, Venzon D, Church J, Farley M, Wheeler S, et al. Lamivudine (3TC) in Children with HIV Infection: A Phase I/II Study. J Infectious Diseases 174(1): 16-25, Jul 1996.
Federici ME, Kline MW, Rutkiewiecz VL, Church JA, Harris AT, Evans K, Kaul S, Wheeler S, et al. A Phase I/II Evaluation of Stavudine (d4T, ZERITÔ) in Children with Human Immunodeficiency Virus Infection. International Antiviral News, December 1995.
Lewis L, Wells M, Church J, Wheeler S, Hall S, Pizzo P, et al. A Phase I/II Study of 3TC (GR109714X) in Children with HIV Infections. Proceedings of the IXTH. International Conference on AIDS, June 6, 1995, p. 478 (abstract).
Wheeler S, Church J. Elevated Serum Neopterin Level as a Marker for Disseminated Mycobacterium
avium-complex in HIV-Infected Children. The Second National Conference on Human Retroviruses and Related Infections, January 29, 1995 (abstract 116).
Lewis L, Mueller R, Schock S, Schock R, Wheeler S, et al. A Phase I/II Study to Evaluate the Safety, Toxicity and Preliminary Efficacy of Combinations of Lamivudine (3TC), Zidovudine (AZT) and Didanosine (ddI) in Children with HIV Infection. The Second National Conference on Human Retroviruses and Related Infections, January 29, 1995 (abstract 265).
AIDS CLINICAL TRIALS INVOLVEMENT AT CHILDRENS HOSPITAL LOS ANGELES
An Observational Research Study of the Rate of Opportunistic Infection Events in HIV-Infected
Children who have Demonstrated Immunologic Reconstitution and who have Discontinued OI Prophylaxis Assess a Phase I/II Study of T-20, A Fusion Inhibitor in HIV-1 Infected Children
A Phase I/II, Research Trial of CD4-IgG2 in HIV-Infected Children.
Bayer Corporation: A Randomized, Double-Blind, Multicenter, Parallel Group Trial Comparing the Safety and Efficacy of IGIV-Chromatography, 10% (Experimental) with IGIV-Solvent Detergent Treated, 10% (Control) in Patients with Primary Immune Deficiency.
Glaxo Wellcome Corporation: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study to Evaluate the Safety and Efficacy of 141W94 Plus Current Nucleoside Therapy versus Current Nucleoside Therapy Alone in Protease-Inhibitor Naive HIV-1 Infected Children.
NIH Sponsored Research: Transduction of CD34+ cells From The Bone Marrow of HIV-1 Infected
Children: Comparative Marking by an RRE Decoy Gene and a Neutral Gene.
Glaxo Wellcome Corporation: A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/ Zidovudine (ZDV) / Lamivudine (3TC) /verses the combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients. Baxter Healthcare Corporation: A Clinical Investigation to Assess the Pharmacokinetics and Acute Safety of Immune Globulin Intravenous (Human) 5% Liquid in Patients with Primary Immunodeficiency Disorders.
ACTG Phase 1/11 Study of Safety and Immunogenicity of Live- Attenuated Varicella Vaccine (Varivax) in
HIV-Infected Children.
CHLA Research Institute: Gene-transfer from bone marrow aspirates.
ACTG Phase I/II to Evaluate the Combination of Lamivudine (3TC), Zidovudine (ZDV), and Didanosine
(ddI) in Children.
ACTG Phase I /II study of HIVIG in slowing Progression of Disease in Children
Biotechnology General Pharmaceuticals: Evaluation of the Effects of Oxandrin on Malnourished HIV-Positive Pediatric Patients.
CHLA AIDS Center: Use of Nontraditional/Alternative Therapy in HIV-Infected Children. CHLA AIDS Center: Caregivers’ Disclosure of HIV to Their Children Infected with HIV.
Baxter Healthcare Corporation: A Phase 4 Study to Assess the Acute and Medium Term Safety of
Gammagard S/D Immune Globulin Intravenous in Patients with Primary Immune Deficiency Disorders.
ACTG Phase I Oral Ganciclovir for Quiescent CMV Infection
ACTG Phase I Valacyclovir for Varicella/Zoster Infections and Herpes Simplex Infections
ACTG Phase II/III Study of Micronized-Atovaquone and Azithromycin as Compared to TMP/SMX for
Phase I Pilot Study of High Dose IVIG on HIV Levels and Activated T-cells
NIH/ Glaxo: Phase I 3TC, AZT + ddI
NIH/ Glaxo: Phase I 3TC for HIV 3 months to 17 years
Bristol Meyers Squibb Phase I d4T for HIV 3 months to 12 years
NIH/Abbott Laboratories: Phase I Clarithromycin for MAI 3 months to 18 years
NIH/CHLA Phase I AZT plus ddI for HIV 3 months to 21 years
